Celldex Therapeutics (CLDX) Other Gross PP&E Adjustments (2016 - 2025)
Celldex Therapeutics has reported Other Gross PP&E Adjustments over the past 15 years, most recently at $17.9 million for Q4 2025.
- Quarterly results put Other Gross PP&E Adjustments at $17.9 million for Q4 2025, up 503.8% from a year ago — trailing twelve months through Dec 2025 was $17.9 million (up 503.8% YoY), and the annual figure for FY2025 was $17.9 million, up 503.8%.
- Other Gross PP&E Adjustments for Q4 2025 was $17.9 million at Celldex Therapeutics, up from -$2.7 million in the prior quarter.
- Over the last five years, Other Gross PP&E Adjustments for CLDX hit a ceiling of $17.9 million in Q4 2025 and a floor of -$3.9 million in Q2 2022.
- Median Other Gross PP&E Adjustments over the past 5 years was -$2.8 million (2021), compared with a mean of $134050.0.
- Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 67.69% in 2024 and later surged 503.8% in 2025.
- Celldex Therapeutics' Other Gross PP&E Adjustments stood at $7.0 million in 2021, then soared by 62.84% to $11.4 million in 2022, then fell by 19.18% to $9.2 million in 2023, then plummeted by 67.69% to $3.0 million in 2024, then surged by 503.8% to $17.9 million in 2025.
- The last three reported values for Other Gross PP&E Adjustments were $17.9 million (Q4 2025), -$2.7 million (Q3 2025), and -$3.1 million (Q2 2025) per Business Quant data.